DiCE Molecules Holding LLC

DiCE Therapeutics, Inc. is a biopharmaceutical company. It designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was founded by J. Kevin Judice on August 14, 2013 and is headquartered in South San Francisco, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was founded by J. Kevin Judice on August 14, 2013 and is headquartered in South San Francisco, CA.

Eli Lilly

Lilly said its acquisition of Dice for $48 a share would allow it to leverage the group's developing treatments for chronic diseases in immunology.

Eli Lilly to Buy Dice Therapeutics in $2.4 Billion Autoimmune Disease Push

Dice Therapeutics Inc. DICE stock is up by 40% in premarket trades Tuesday after it agreed to be purchased by Eli Lilly & Co. LLY for $48 a share in a deal that values the immunology company at about $2.4 billion. The price values Dice at a 40% premium over the 30-day, volume-weighted average trading price of its stock as of June 16.

Dice Therapeutics rallies as it agrees to be bought by Lilly

Eli Lilly and Co will buy Dice Therapeutics Inc in an all-cash deal worth about $2.4 billion to boost its autoimmune drug portfolio, the companies said on Tuesday.

Eli Lilly to buy Dice Therapeutics in $2.4 billion deal

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif. , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE.

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

SOUTH SAN FRANCISCO, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today announced that management will host a research & development (R&D) day on Tuesday, June 20, 2023 from 12:00 p.m. – 2:30 p.m. ET in New York, NY. The event will highlight progress on DICE's clinical-stage and discovery programs as well as key aspects of the company's DELSCAPE platform.

DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023

Canaccord Genuity (TSX:CF, LSE:CF) analysts have initiated coverage of DICE Therapeutics, Inc, a biopharmaceutical company focused on treating chronic autoimmune and inflammatory diseases, Monday with a ‘Buy' rating and a 12-month target price of $71 per share, noting the company's lead compound DC-806 for treating plaque psoriasis (PsO) has “blockbuster potential”.    The analysts wrote that they believe DICE is poised for clinical success, given the company's R&D strategy of selecting drug targets that are: 1) proven to be effective for indications with high prevalence; 2) clinically and commercially validated by approved biologics; and 3) known to have structural features that support potent small molecule binding.

DICE Therapeutics psoriasis treatment has blockbuster potential, analysts say

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate achievements.

DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today announced management will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 3:00 p.m. PT / 6:00 p.m. ET.

DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today announced management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 4:00 p.m. ET.

DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate achievements.

DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that data from its Phase 1 proof-of-concept clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17, will be presented in a late-breaking oral session at the 2023 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 17-21 in New Orleans, LA.

DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will participate at the following investor conferences:

DICE Therapeutics to Participate at Upcoming Investor Conferences

DICE Therapeutics: Oral Drug Of Proven IL-17 Target

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PST / 3:00 p.m. EST.

DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Here is how DICE Therapeutics, Inc. (DICE) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.

Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year?

Here is how DICE Therapeutics, Inc. (DICE) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.

Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?

Here is how DICE Therapeutics, Inc. (DICE) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.

Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year?

The average of price targets set by Wall Street analysts indicates a potential upside of 92.5% in DICE Therapeutics, Inc. (DICE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think DICE Therapeutics, Inc. (DICE) Could Surge 93%: Read This Before Placing a Bet

Axsome Therapeutics

Lantheus Holdings

The good times could keep on rolling for these big winners.

These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today reported financial results and business highlights for the third quarter ended September 30, 2022.

DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the following investor conferences:

DICE Therapeutics to Present at Upcoming Investor Conferences

DICE Therapeutics is a recent IPO. Recently, it came out with positive data from its lead asset.

DICE Therapeutics: Moving Things Along Nicely

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the closing on October 17, 2022 of its previously announced upsized underwritten public offering of 9,452,054 shares of its common stock, including the full exercise of the underwriters' option to purchase 1,232,876 additional shares, at a public offering price of $36.50 per share. All shares of common stock were offered by DICE. The gross proceeds to DICE from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $345.0 million.

DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the pricing of its upsized underwritten public offering of 8,219,178 shares of its common stock at a public offering price of $36.50 per share. All shares of common stock are being offered by DICE. The gross proceeds to DICE from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $300.0 million. In addition, DICE has granted the underwriters a 30-day option to purchase up to an additional 1,232,876 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about October 17, 2022, subject to the satisfaction of customary closing conditions.

DICE Announces Pricing of Upsized Public Offering of Common Stock

DICE Therapeutics (DICE) reports positive top-line data from a phase I study, evaluating its lead candidate DC-806 for treating psoriasis. Stock up.

News for DiCE Molecules Holding LLC Stock (DICE)